Results 141 to 144 of about 10,090 (144)

Creation of a long-acting nanoformulated dolutegravir

Nature Communications, 2018
Brady Sillman, Aditya N Bade, Prasanta K Dash   +2 more
exaly  

Dolutegravir

Reactions Weekly, 2016
openaire   +1 more source

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Lancet HIV,the, 2018
Indira Brar, Daniel Podzamczer
exaly  

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Clinical Infectious Diseases, 2020
exaly